Literature DB >> 16719060

Neural repair strategies for Parkinson's disease: insights from primate models.

Katherine Soderstrom1, Jennifer O'Malley, Kathy Steece-Collier, Jeffrey H Kordower.   

Abstract

Nonhuman primate models of Parkinson's disease (PD) have been invaluable to our understanding of the human disease and in the advancement of novel therapies for its treatment. In this review, we attempt to give a brief overview of the animal models of PD currently used, with a more comprehensive focus on the advantages and disadvantages presented by their use in the nonhuman primate. In particular, discussion addresses the 6-hydroxydopamine (6-OHDA), 1-methyl-1,2,3,6-tetrahydopyridine (MPTP), rotenone, paraquat, and maneb parkinsonian models. Additionally, the role of primate PD models in the development of novel therapies, such as trophic factor delivery, grafting, and deep brain stimulation, are described. Finally, the contribution of primate PD models to our understanding of the etiology and pathology of human PD is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16719060     DOI: 10.3727/000000006783982025

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  12 in total

1.  Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.

Authors:  Christopher A Lieu; Milind Deogaonkar; Roy A E Bakay; Thyagarajan Subramanian
Journal:  Parkinsonism Relat Disord       Date:  2010-11-11       Impact factor: 4.891

2.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

3.  Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys.

Authors:  Liming Luan; Feng Ding; Yi Ai; Anders Andersen; Peter Hardy; Eric Forman; Greg A Gerhardt; Don M Gash; Richard Grondin; Zhiming Zhang
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

Review 4.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

5.  Sorting protein-related receptor SorLA controls regulated secretion of glial cell line-derived neurotrophic factor.

Authors:  Zhao Geng; Feng-Yi Xu; Shu-Hong Huang; Zhe-Yu Chen
Journal:  J Biol Chem       Date:  2011-10-12       Impact factor: 5.157

6.  Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion.

Authors:  Marco Timmer; Konstantin Cesnulevicius; Christian Winkler; Julia Kolb; Esther Lipokatic-Takacs; Julia Jungnickel; Claudia Grothe
Journal:  J Neurosci       Date:  2007-01-17       Impact factor: 6.167

7.  Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys.

Authors:  Feng Ding; Liming Luan; Yi Ai; Ashley Walton; Greg A Gerhardt; Don M Gash; Richard Grondin; Zhiming Zhang
Journal:  Exp Neurol       Date:  2008-05-03       Impact factor: 5.330

Review 8.  The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions.

Authors:  Alan Regenberg; Debra J H Mathews; David M Blass; Hilary Bok; Joseph T Coyle; Patrick Duggan; Ruth Faden; Julia Finkel; John D Gearhart; Argye Hillis; Ahmet Hoke; Richard Johnson; Michael Johnston; Jeffrey Kahn; Douglas Kerr; Patricia King; Joanne Kurtzberg; S Matthew Liao; John W McDonald; Guy McKhann; Karin B Nelson; Mahendra Rao; Andrew W Siegel; Kirby Smith; Davor Solter; Hongjun Song; Jeremy Sugarman; Angelo Vescovi; Wise Young; Henry T Greely; Richard J Traystman
Journal:  J Cereb Blood Flow Metab       Date:  2008-08-27       Impact factor: 6.200

9.  Generation of transgenic cynomolgus monkeys that express green fluorescent protein throughout the whole body.

Authors:  Yasunari Seita; Tomoyuki Tsukiyama; Chizuru Iwatani; Hideaki Tsuchiya; Jun Matsushita; Takuya Azami; Junko Okahara; Shinichiro Nakamura; Yoshitaka Hayashi; Seiji Hitoshi; Yasushi Itoh; Takeshi Imamura; Masaki Nishimura; Ikuo Tooyama; Hiroyuki Miyoshi; Mitinori Saitou; Kazumasa Ogasawara; Erika Sasaki; Masatsugu Ema
Journal:  Sci Rep       Date:  2016-04-25       Impact factor: 4.379

Review 10.  Allopregnanolone and neurogenesis in the nigrostriatal tract.

Authors:  Jun Ming Wang
Journal:  Front Cell Neurosci       Date:  2014-08-12       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.